

بِسْمِ اللَّهِ الرَّحْمَنِ الرَّحِيمِ

قال الله تعالى

اللَّهُ نُورُ السَّمَاوَاتِ وَالْأَرْضِ مِثْلُ نُورِهِ كَمِشْكَاةٍ فِيهَا  
مِصْبَاحٌ الْمِصْبَاحُ فِي زُجَاجَةٍ الزُّجَاجَةُ كَأَنَّهَا كَوْكَبٌ  
دُرِّيُّ يُوقَدُ مِنْ شَجَرَةٍ مَبَارَكَةٍ زَيْتُونَةٍ لَا شَرْقِيَّةٍ وَلَا  
غَرْبِيَّةٍ يَكَادُ زَيْتُهَا يُضِيءُ وَلَوْ لَمْ تَمْسَسْهُ نَارُ نُورٍ عَلَى  
نُورٍ يَهْدِي اللَّهُ لِنُورِهِ مَن يَشَاءُ وَيَضْرِبُ اللَّهُ الْأَمْثَالَ  
لِلنَّاسِ وَاللَّهُ بِكُلِّ شَيْءٍ عَلِيمٌ

صدق الله العظيم

سورة النور الآية 35

## **Dedication**

This thesis is dedicated to the soul of my father, who taught me that the best kind of knowledge to have is that which is learned for its own sake. It is also dedicated to my mother, who taught me that even the largest task can be accomplished if it is done one step at a time.

This thesis work is dedicated to my husband, Mohmmmed, who has been a constant source of support and encouragement during the challenges of graduate school and life. I am truly thankful for having you in my life. This work is also dedicated to my sons, my sisters and my brothers, who have always loved me

## Acknowledgements

Foremost, I would like to express my sincere gratitude to my supervisor Dr. Nadia Madni for the continuous support of my research, her patience, motivation, enthusiasm, and immense knowledge. Her guidance helped me in all the time of research and writing of this thesis.

Besides my advisor, I would like to thank my colleague Salaheldeen Elzaki for his help, advise, encouragement and insightful comments.

My sincere thanks also go to the staff of molecular epidemiology laboratory at tropical medicine research institute for their help and hosting me in their lab to carry out my practical work.

Last would like to thank all of the women who participated in this Study.

## Abstract

This study was carried out Khartoum State at Khartoum Isotope Radiation Centre (RICK), from the period April –September 2013, to study the methalanetertahydrofloate reductase polymorphism with breast cancer risk, and to compare it with normal population. 96 individuals were included in this study of which 60 patients with breast cancer originating from different ethnic group and part of Sudan, and 36 were women without breast cancer as normal controls.

Five ml EDTA blood was taken for hematological parameters. All of our studies patients had low hemoglobin level below 10 gm/dl (p-value=0.127)insignificant, and 15% of the patients had thrombocytopenia(less than 150.000/cum) p-value=0.2) insignificant, 50% of the studies group had normal WBCs(4000-6900), 30% had increased WBC count(more than 7000/cum) ( and 20% had decreased WBC count(less than 4000/cum) P-value=0.365)insignificant.

A cross sectional hospital based study was conducted in this study.

16.7% of breast cancer patients had TC alleles of *MTHFR* and none of the controls had mutation (Chi seque test=6.96. *P.value*=0.01), the results showed highly significant of the TC mutation compared with normal controls.

The majority of the breast cancer patients whom had TC alleles were women under 40 years, and this could be risk of having breast cancer.

high frequency of breast cancer had been observed among northern State.

اجريت هذه الدراسة فى الفترة من ابريل -اغسطس 2013 فى ولاية الخرطوم المركز القومى للعلاج بالذرة لدراسة انزيم الميثايلين تتراهدروفوليت ومدى تاثيره على سرطان الثدي عند النساء فى ولاية الخرطوم وذلك باستخدام تقنية البلمرة الجينية فى حالت وجود طفرة جينية مقارنة بنساء اصحاء

تم اختيار ستون مريضة بسرطان الثدي بعد التشخيص , ست و ثلاثون عينة من الاصحاء كمجموعة ضبط,وقد تم اخذ خمسة مليمتر من الدم الوريدى من كل مريض فى اثنين انبوب به مانع من التجلط واحدة لقياس نسبة الهيمقلوبين وعدد كريات الم البيضاء و الصفائح الدموية و الاخرى لفصل الحمض النووى وكانت النتائج فى كل شريحة الدراسة لديهم نقصان فى قياس نسبة الهيمقلمبين وهى اقل من عشرة جرام فى الديسليتر وهى تعتبر نسبة ضعيفة ,كما وجدت عدد كريات الدم البيضاء عشرون فى المائة اقل من الطبيعى (اقل من اربعة الف فى المليمتر المكعب) , و ثلاثون فى المائة اكثر من الطبيعى (اكثر من سبعة الف) وخمسون فى المائة لديهم عدد طبيعى للكريات البيضاء , اما الصفائح الدموية خمسة عشر فى المائة (اقل من الطبيعى) (اقل من مائة و خمسون الف فلى المليمتر المكعب

كما لوحظ ان ستة عشر وسبعة من عشرة فى المائة من المرضى المصابين بسرطان الثدي لديهم طفرة جنية للانزيم كما لاتوجد هذه الطفرة عند الاصحاء وعند استخدام برنامج الهزم . الاحصائية .كانت قيمة الاختبار واحد من مائة

وجدت ان غالبية المرضى فى الفئة العمرية ما بين ثلاثون الى اربعين عام كما ان الولاية الشمالية هى الاكثر انتشارا للمرض لذلك نوصى بعمل دراسة تشمل الفئة العمرية و المنطقة المذكورتين

## Table of Contents

Contents	Page No
الإية	I
Dedication	II
Acknowledgements	III
Abstract	IV
Abstract Arabic	V
Table of contents	VI
List of Tables	IX
List of figures	X
List of a privations	XI
<b>Chapter One</b> <b>Introduction and literature review</b>	
1.1 Breast cancer	1
1.2 Risk factors	2
1.3 Lifestyle	2
1.4 Association between oral contraceptive breast cancer	2
1.5 Chemicals and radiation	2
1.6 Genetics	3
<b>1.7 Pathophysiology and Carcinogenesis</b>	3
<b>1.8 Diagnosis</b>	4
1.9 Breast cancer classification	4
1.10 Breast cancer screening	6
1.11 The Burden of Breast cancer in Sudan	7
1.12 Heamoglobin	8
1.13 White blood cells or leukocytes	8
1.14 Platelets	9
1.15 Methylenetetrahydrofolate reductase (MTHFR)	9
1.16 Effect of low folate and <i>MTMFR</i> mutation	11
1.17 Folic acid	12
1.18 <i>MTHFR</i> and modulaton the chemosensitivity of cancer cells	13
1.19 Rationale	14
1.20 Objectives of the study	15
1.21. 1General objectives	15
1.22.2 Specific objectives	15
<b>Chapter Two</b> <b>Materials and methods</b>	
2.1 Study area	16

2.2 Study population	16
2.3 Sample size	16
2.4 Inclusion Criteria	17
2.5 Exclusion Criteria	17
2.6 Ethical consideration:	17
2.7 Blood Sample	17
2.8 Hemoglobin determination	18
<b>2.9 White Blood Cell Count (WBC)</b>	18
2.10 Platelets count	18
2.11 Buffy coat preparation	19
<b>2.12 DNA extraction</b>	19
2.13 DNA quantitation (Gene Quant)	19
<b>2.14 DNA and reagents storage conditions</b>	20
2.15 Polymerase Chain Reaction (PCR)	20
2.16 Master Mix preparation	20
2.17 Tempature profile of the primer sequences flanking region 677	20
2.18 DNA visualization	21
2.19 Digestion of <i>mthfr</i> gene by restriction fragment polymorphism (RFLP)	21
2.20 Detection of <i>mthfr</i> gene mutation	21
2.21 Statistical Methods	21
<b>Chapter Three Results</b>	
3.1 Geographical distribution of the patients and controls	22
3.2 Characteristic of the normal controls	22
3.3 Distribution of the study group according to age	23
3.4 Distributions of the study group according to family history of breast cancer	23
3.5 Hematological parameters	24
3.6 Amplification of <i>MTHFR</i> 677 gene	26
3.7 Restriction Fragment Length Polymorphism of <i>MTHFR</i> 677	27
3.8 Genotype of <i>MTHFR</i> alleles of the patients compared with controls	27
3.9 Genotyping and history of breast cancer	28
3.10 Association of <i>Mthfr</i> genotyping and geographical location	29
<b>Chapter Four 4. Discussion, conclusion and recommendations</b>	

4.1 Discussion	30
4.2 Conclusions	32
4.3 Recommendations	32
References	33
Appendix	39



### List of Tables

content	Page
Table 3.1 showed MTHFR alleles in patients with breast cancer	27
Table 3.2 history of breast cancer and genotype	29
<b>Table3.3 Main characteristics of the MTHFR genetic variants analyzed in this study</b>	29
Table 3.4 Allele and genotype frequencies for breast cancer risk factors	29
<b>Table 3.5 of geographical location</b>	29

## List of Figures

<b>contents</b>	<b>page</b>
Figure 1.1 Mammograms showing a normal breast (left) and a cancerous breast (right).	<b>7</b>
Figure 1.2 MTHFR gene locations on chromosome 1(NCBI)	<b>11</b>
Figure 2.1 Khartoum State Map	<b>16</b>
Figure 3.1 Geographical Distribution of the patients	<b>22</b>
Figure 3.2 study group according to age	<b>23</b>
Figure 3.3 Distributions of the study group according to family history of breast cancer	<b>23</b>
Figure 3.5 white blood cells count in patients with breast cancer	<b>24</b>
Figure 3.7 showed relation between WBC in the treated and untreated patients	<b>25</b>
Figure 3.8 showed correlation of mean platelets in the treated and untreated patients	<b>62</b>
Figure 3.9 MTHFR 766 PCR products on 1.5% agarose gel, lane 1 molecular weight marker 100 bp, 1-5 were samples.	<b>26</b>
Figure 3.10 Digested with Hinf1: Lane 1 molecular weight marker 100 bp, 2,5 and 7 were TC, and 3,4 and 6 were TT genotype	<b>27</b>
Figure 3.11 MTHFR genotype of patient's breast cancer	<b>28</b>
Figure 3.12 Association of TC genotype with age group	<b>28</b>
Appendix (5) Showed Invasive Breast Cancer	<b>44</b>
Appendix (5) stage 1 breast cancer	<b>44</b>

### **List of A privation**

FNAC:	Fine Needle Spiration cytologyy.
Dump:	Uridine mono phophate
TMP:	Thymidine mono phosphate.
FAD:	Flavin adenine dinuclotide.
MTHFR:	Methylenetetrahydrofolate Reductase.
FA:	Folic Acid.